Kaliumphosphat B. Braun (Dipotassium Phosphate, Potassium Dihydrogen Phosphate)

Dipotassium phosphate dissociates after intravenous infusion, releasing potassium and phosphate ions into the extracellular fluid. The potassium helps re‑establish normal membrane potentials and cardiac function, while phosphate is essential for ATP production, cellular signaling, and buffering of acid‑base balance. Together they support metabolic processes and stabilize electrolyte homeostasis.

The prescribed dose of Kaliumphosphat B. Braun is individualized by the treating clinician based on the patient’s serum electrolyte levels, renal function, clinical status, and the specific indication. The prescriber calculates the amount needed to safely raise potassium and phosphate concentrations to target ranges, following institutional protocols.

Safety data for Kaliumphosphat B. Braun in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should evaluate the potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing patients.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Kaliumphosphat B. Braun provides both potassium and phosphate in a single formulation, which can simplify therapy compared with using separate potassium chloride and phosphate preparations. It offers rapid intravenous correction, whereas oral supplements act more slowly. Choice of product depends on the clinical scenario, required ion concentrations, and compatibility with other IV fluids.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration. Keep the solution in its original packaging until administration to maintain sterility and stability.

Kaliumphosphat B. Braun is administered intravenously, typically via a peripheral or central line. The infusion rate is determined by the prescriber and may be adjusted based on real‑time monitoring of serum electrolytes and the patient’s cardiac status. Compatibility with other IV solutions should be confirmed before mixing.

The most serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, and hyperphosphatemia leading to calcium‑phosphate precipitation and tissue injury. Rapid infusion may also provoke hypotension or metabolic alkalosis. Prompt monitoring of electrolytes and cardiac rhythm is essential to mitigate these hazards.

Patients with known hypersensitivity to dipotassium phosphate, potassium dihydrogen phosphate, or any excipients in the formulation should avoid the product. It is also contraindicated in individuals with severe renal failure unable to excrete excess phosphate or potassium, and in those with uncontrolled hyperkalemia or hyperphosphatemia.